MedTrace Logo

RDEA119 and Sorafenib Combination Dose Escalation Study

NCT00785226 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2016-10-17

No results posted yet for this study

Summary

Phase 1/2 dose escalation study to investigate the combination of RDEA119 and sorafenib in advanced cancer patients.

Conditions

Interventions

DRUG

RDEA119

Total daily doses of RDEA119 from 10 mg/day to 100 mg/day

DRUG

Sorafenib

Total daily doses of sorafenib from 400 mg/day to 800 mg/day.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00785226 on ClinicalTrials.gov